Fertility Preservation Before Gonadotoxic Medical Therapies: Evidence, Strategies, and Clinical Considerations

Abstract

Gonadotoxic medical therapies, especially chemotherapy and radiotherapy, pose a significant risk to reproductive function in patients of reproductive age. Timely intervention for fertility preservation is crucial to mitigate the long-term consequences of treatment on future reproductive potential. This review synthesizes the latest evidence, explores mechanisms of gonadotoxicity, outlines risk factors, and evaluates current and emerging fertility preservation strategies. The article also analyzes recent guidelines, providing practical clinical insights for healthcare professionals managing patients facing gonadotoxic treatments.

Introduction

The advent of advanced oncologic and immunosuppressive therapies has markedly improved survival rates in malignancies and systemic diseases. However, these therapies often carry the unintended consequence of gonadal damage, resulting in temporary or permanent infertility. As survivorship increases, quality of life issues, including fertility, have become central to comprehensive patient care. There is a growing imperative for clinicians to understand the risks associated with gonadotoxic treatments and to integrate evidence-based fertility preservation strategies into patient management pathways. This article provides a detailed review of the scientific and clinical aspects of fertility preservation in patients undergoing gonadotoxic therapies, emphasizing the importance of early intervention and multidisciplinary collaboration.

Epidemiology / Disease Burden

Globally, over one million individuals of reproductive age are diagnosed with cancer annually, with a substantial proportion requiring chemotherapy, radiotherapy, or bone marrow transplantation. The prevalence of iatrogenic infertility is on the rise, paralleling improved survival rates in pediatric and young adult oncology. Studies estimate that up to 80% of women treated with alkylating agents and 50% of men receiving certain chemotherapies may experience significant fertility impairment. Non-oncologic conditions such as autoimmune diseases and hematological disorders also contribute to the burden due to their requirement for gonadotoxic immunosuppressive regimens. The psychosocial impact of infertility is profound, affecting quality of life and long-term psychological wellbeing, further underscoring the need for proactive fertility preservation discussions.

Pathophysiology

Gonadotoxicity arises from the direct cytotoxic effects of medical therapies on germ cells, supporting somatic cells, and the vascular microenvironment of the gonads. In females, chemotherapeutic agents especially alkylating agents induce apoptosis in primordial follicles, depleting the ovarian reserve. Radiotherapy can cause DNA double-strand breaks and vascular insufficiency, accelerating follicular atresia. In males, similar agents disrupt spermatogenesis by targeting rapidly dividing spermatogonia and damaging Sertoli and Leydig cells. The degree of gonadal damage is influenced by patient age, baseline reproductive function, cumulative drug dose, radiation field, and genetic susceptibility, with prepubertal patients being less vulnerable but not immune to long-term sequelae.

Risk Factors

Key risk factors for gonadotoxicity include the type and cumulative dose of chemotherapy (notably alkylating agents such as cyclophosphamide and busulfan), pelvic or total-body irradiation, and the use of high-dose conditioning regimens for stem cell transplantation. Age at exposure is critical, with older females having a diminished ovarian reserve and an increased risk of premature ovarian insufficiency. Pre-existing subfertility, prior gonadal surgery, and genetic predispositions (such as BRCA mutations) may further exacerbate vulnerability. Comorbid conditions like systemic lupus erythematosus that require chronic immunosuppression also elevate risk profiles for both sexes.

Clinical Features

Clinical manifestations of therapy-induced gonadotoxicity vary by sex and age. In females, features include irregular menses, amenorrhea, menopausal symptoms, and, ultimately, infertility. Biochemical markers such as elevated follicle-stimulating hormone (FSH) and low anti-Müllerian hormone (AMH) reflect diminished ovarian reserve. In males, reduced testicular volume, oligospermia, or azoospermia are common, accompanied by low serum inhibin B and elevated FSH. Additional sequelae may involve hypogonadism, sexual dysfunction, and negative impacts on bone health and cardiovascular risk due to hormonal deficiency.

Diagnosis

Assessment of gonadal reserve prior to initiating gonadotoxic therapy is fundamental. In females, transvaginal ultrasonography to assess antral follicle count (AFC) and serum AMH, FSH, and estradiol levels are standard. In males, baseline semen analysis, serum FSH, luteinizing hormone (LH), and testosterone provide an overview of spermatogenic capacity. Genetic counseling may be warranted in select cases. Reproductive endocrinology consultation should be offered to all at-risk patients, ideally before therapy commences, to enable informed decision-making regarding fertility preservation options.

Treatment & Management

Fertility preservation strategies must be individualized, considering patient age, cancer type, treatment urgency, and personal preferences. Established options for females include embryo cryopreservation, oocyte cryopreservation, and, in select cases, ovarian tissue cryopreservation. Embryo and oocyte cryopreservation require controlled ovarian stimulation, which may not be feasible in acute settings. Ovarian transposition (oophoropexy) may be indicated prior to pelvic irradiation. For males, sperm cryopreservation remains the gold standard and should be offered pre-treatment. Experimental approaches, such as testicular tissue cryopreservation, are under investigation for prepubertal boys. Gonadotropin-releasing hormone (GnRH) analogs are sometimes used for ovarian protection, though data on efficacy are mixed and they are not a substitute for established cryopreservation methods.

Recent Advances / Emerging Therapies

Emerging technologies are expanding the landscape of fertility preservation. Vitrification has improved oocyte and embryo survival rates post-thaw. Ovarian tissue cryopreservation and transplantation have resulted in successful pregnancies, offering hope to prepubertal girls and women unable to delay therapy. In vitro maturation (IVM) of oocytes and artificial gametogenesis are promising experimental modalities. Preclinical research into pharmacologic gonadoprotectants, such as sphingosine-1-phosphate and AS101, is ongoing. For males, advances in spermatogonial stem cell transplantation and in vitro spermatogenesis hold potential for future clinical translation. Robust ethical frameworks and long-term safety data are essential as these technologies evolve.

Guideline Recommendations

Multiple professional societies, including ASCO, ESMO, and ASRM, advocate for early discussion of fertility risks and preservation options with all patients of reproductive age prior to gonadotoxic therapy. Guidelines emphasize multidisciplinary approaches involving oncologists, reproductive specialists, and counseling services. Embryo and oocyte cryopreservation are recommended as standard of care. Ovarian tissue cryopreservation is no longer considered experimental for postpubertal females. Sperm banking should be offered to all postpubertal males. Documentation of counseling and patient decisions is required. Timely referral and streamlined protocols are critical to minimize treatment delays.

Conclusion

Fertility preservation is an essential component of comprehensive care for patients undergoing gonadotoxic medical therapies. Early identification of at-risk individuals, informed patient counseling, and timely implementation of evidence-based preservation strategies can safeguard reproductive potential and improve quality of life for survivors. Continued research and refinement of emerging therapies will further enhance options available to patients. A collaborative, guideline-driven approach is warranted to optimize clinical outcomes and address the long-term reproductive needs of this growing patient population.